Department of Biochemistry, Government College University, Faisalabad, Pakistan.
Department of Physics and Bernal Institute, University of Limerick, Limerick, Ireland.
Drug Discov Today. 2023 Jun;28(6):103577. doi: 10.1016/j.drudis.2023.103577. Epub 2023 Mar 31.
In recent years, immunotherapy for cancer treatment using monoclonal antibodies has shown clinical success, particularly with programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1). Dostarlimab, an immune checkpoint inhibitor, interacts with adaptive immunity by binding to human PD-1, inhibiting PD-L1 and PD-L2 interactions, and cross-talk with adaptive immunity. Recent clinical trials have shown that dostarlimab is effective in treating mismatch repair deficiency (dMMR) in endometrial cancer patients, leading to its approval in the United States and the European Union in 2021. This article provides a comprehensive overview of dostarlimab, its therapeutic ability, and the different indications for which it is being used. Dostarlimab could serve as a potential alternative to many cancer treatments that frequently have severe consequences on patients' quality of life.
近年来，使用单克隆抗体的癌症治疗免疫疗法取得了临床成功，特别是程序性细胞死亡蛋白 1（PD-1）及其配体程序性死亡配体 1（PD-L1）。Dostarlimab 是一种免疫检查点抑制剂，通过与人 PD-1 结合，抑制 PD-L1 和 PD-L2 的相互作用以及与适应性免疫的串扰，与适应性免疫相互作用。最近的临床试验表明，dostarlimab 对治疗子宫内膜癌患者的错配修复缺陷（dMMR）有效，因此该药于 2021 年在美国和欧盟获得批准。本文全面概述了 dostarlimab 的治疗能力及其不同的适应证。Dostarlimab 可能成为许多癌症治疗方法的潜在替代方法，这些方法常常对患者的生活质量产生严重影响。
